Cotinine analytical workshop report: consideration of analytical methods for determining cotinine in human body fluids as a measure of passive exposure to tobacco smoke. by Watts, R R et al.
Environmental Health Perspectives
Vol. 84, pp. 173-182, 1990
Cotinine Analytical Workshop Report:
Consideration of Analytical Methods for
Determining Cotinine In Human Body Fluids
as a Measure of Passive Exposure to
Tobacco Smoke*
by Randall R. Watts,t John J. Langone,* George J. Knight,§
and Joellen Lewtast
A two-day technical workshop was convened November 10-11, 1986, to discuss analytical
approaches for determining trace amounts of cotinine in human body fluids resulting from pas-
sive exposure to environmental tobacco smoke (ETS). The workshop, jointly sponsored by the U.S.
Environmental Protection Agency and Centers for Disease Control, was attended by scientists
with expertise in cotinine analytical methodology and/or conduct of human monitoring studies
related to ETS. The workshop format included technical presentations, separate panel discussions
on chromatography and immunoassay analytical approaches, and group discussions related to the
quality assurance/quality control aspects of future monitoring programs. This report presents a
consensus of opinion on general issues before the workshop panel participants and also a detailed
comparison of several analytical approaches being used by the various represented laboratories.
The salient features of the chromatography and immunoassay analytical methods are discussed
separately.
Introduction
Environmental tobacco smoke (ETS) has increas-
ingly become a health concern since a series of epide-
miological studies between 1981 and 1986 (1-6)
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reported an association between tobacco smoke expo-
sure and increased risk of human lung cancer. Hum-
ble and co-workers (7) recently confirmed the health
risk conclusions of earlier researchers and reported
that people who never smoked and were married to
smokers had about a 2-fold increased risk of lung
cancer.
Methods for determining the degree of exposure of
individuals has received much attention in recent
years, and various biological markers have been stud-
ied as surrogate analytes for determining exposures.
A general consensus is that the nicotine metabolite,
cotinine, has the prerequisites of specificity, retention
time in the body, and detectable concentration levels
that make it the analyte of choice for quantifying
exposures. In recent years a number of procedures
have been reported for determining cotinine in
human body fluids. The majority of these procedures
use either a chromatographic technique or some form
of immunoassay analysis.
This paper is a report from the two-day Cotinine
Analytical Workshop, which was attended by invited
health scientists and analytical chemists recognized
for their expertise in studies of population exposure1WATTS ETAL.
to ETS and/or analytical methodology related to
these studies. The workshop was jointly sponsored by
the U.S. Environmental Protection Agency (EPA) and
Centers for Disease Control (CDC) and was attended
by 32 scientists who shared their expertise in immu-
noassay or chromatography methods for cotinine and
provided guidance for developing and establishing
related programs for determining passive exposures
to tobacco smoke. The meeting objective was to com-
pare the various analytical approaches to cotinine
analysis and to make recommendations regarding the
general aspects of establishing and conducting moni-
toring programs. Discussions included quality assur-
ance/quality control (QA/QC) programs to support
cotinine monitoring studies and also the possibility of
conducting a future interlaboratory methods compar-
ison study. The diverse analytical approaches repre-
sented by chromatography and immunoassay
methods for cotinine were separately discussed and
reported by respective work groups. The purpose of
this communication is to summarize discussions from
the immunoassay and chromatography work groups
relevant to the aforementioned topics and to convey
the workshop general consensus on other joint issues
including QA/QC aspects of ETS studies.
Chromatography Group Report
The workshop participants with expertise in devel-
oping and applying chromatography methods for
determining cotinine in biological fluids met in a one-
day session. The goal of this session was to develop a
group consensus on several key issues including a)
general method considerations and approaches, b)
QA/QC programs to support cotinine monitoring
studies, and c) considerations related to conducting
an interlaboratory methods comparison study. The
following is a summary of the chromatography group
discussions and a draft of their recommendations
related to topics a and c. The QA/QC recommenda-
tions are contained in a separate section.
General Method Considerations
Sample Type. The body fluids discussed for moni-
toring tobacco smoke exposure included blood serum,
saliva, and urine. Group consensus was that all three
are generally acceptable; however, the choice of a body
fluid to analyze should be predicated on the goals of
the specific monitoring program. For studies that
require a quantitative assessment of exposure, blood
was recommended by the group as the fluid of choice
(8). Saliva was also considered acceptable, and good
correlations were reported between saliva and blood
for results from the same subject (9). Sample collection
considerations, however, resulted in the selection of
blood as the sample medium offirst choice. Analysis of
either blood or saliva for cotinine permits an estimate
of the degree of exposure to tobacco smoke in persons
passively exposed at home or in the work place. While
cotinine determination in urine was also recommended
for estimating exposure, it was generally felt that esti-
mation based on urinary cotinine excretion would be
less reliable than estimation based on plasma or sali-
vary levels. Cotinine excretion is variable across and
within individuals depending on renal function, urine
flow rate, and urine pH (10). Urine results may be
expressed as micrograms of cotinine per milligram of
creatinine in order to correct, in part, for the variable
dilution effects. This correction or normalization, how-
ever, introduces additional variability since this
requires another analytical determination (and oppor-
tunity for experimental error), and creatinine excre-
tion rates for individuals are also variable. Horstmann
(11) reported creatinine excretion rate for 56 subjects
to be 1.11 ± 0.68 g/day (mean ± SD). Hoffman and
Brunneman (12) also found 13 nonsmokers on a con-
trolled diet to have creatinine values of 1.65 ± 0.5 g per
24 hr urine (mean ± SD). The coefficients of variation
between subjects for these two studies were 61 and
30%, respectively.
Sample Collection and Handling. Chromatogra-
phy procedures for cotinine generally require analysis
of a 1 mL sample with an additional 1 mL volume
needed for reanalysis. A total sample volume of 2.5 to
3.0 mL was therefore recommended. Glass and/or
polypropylene sample tubes with screw cap closures
were recommended. The polypropylene tubes were pre-
ferred to avoid breakage during shipment. Minimum
size sample tubes were suggested to reduce volume
losses from freeze drying during long-term storage.
Blood should be centrifuged at the field site and the
serum samples frozen prior to shipment to the labora-
tory. Urine should be frozen soon after collection to
prevent bacterial degradation of the sample. Saliva
may be collected by expectoration into a sample tube;
however, an alternative saliva collection procedure
that uses highly adsorbent dental rolls is recom-
mended (13). The subject is asked to place a dental
roll in the mouth for approximately 15 min. The sam-
ple is then placed in a tube and frozen prior to ship-
ment to the laboratory. The thawed sample is
regenerated at the laboratory by placing the dental
roll in a glass syringe and compressing with a glass
plunger. The resultant clear liquid may then be ali-
quoted for analysis.
Shipment in a frozen condition with dry ice was
recommended for all three sample types to prevent
bacterial degradation of the sample matrix. Loss or
degradation of the cotinine analyte was not consid-
ered to be a problem since participants had found this
compound to be stable.
Upon receipt at the laboratory, samples should be
placed in a freezer (approximately -20°C) until ana-
lyzed. Samples that will be held in excess of one year
should be stored at -80°C. No cotinine degradation
problems were reported for frozen samples. Precau-
tions were recommended, however, to prevent concen-
tration errors resulting from freeze-drying of
samples stored over one year in a frost-free freezer.
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Analytical Method Considerations
The group consensus was that the analytical
method should permit the determination of nicotine
and cotinine in a single analysis and should allow a
clear separation and distinction between these and
other analytes that may be present. The method
should be sufficiently sensitive to give good definition
of passive exposure and thereby yield analytical
results which will show a distinction, for example,
between a child or other nonsmoker that is exposed in
the home and one that is not. Tables 1 and 2 list the
range of detection limits for both chromatography
and immunoassay methods.
The importance of this sensitivity consideration
was supported by the 1981 report of Hirayama (1) and
the 1987 report of Humble et al. (7) which showed an
increased risk of lung cancer for a spouse exposed to a
smoker in the home. Russell reported that cotinine
levels in children's saliva averaged 0.44 ± 0.68 ng/mL
where no parents are smokers, 1.31 ± 1.21 ng/mL
where only the father smoked, 1.95 ± 1.71 where only
the mother smoked, and 3.38 ± 2.45 ng/mL where
both parents are smokers (13). This study used an
analytical method with a detection and quantification
limit of 0.1 ng/mL, which permitted classification of
the lowest exposures into exposure distributions dif-
fering by only 0.1 ng/mL. Over 30% of the children
from nonsmoking homes had cotinine concentrations
below the 0.1 ng/mL detection limit. In the groups
where one or more parents smoked, the cotinines were
significantly (p < 0.01) elevated, and 50% of the chil-
dren of the lowest exposed group had less than 1 ng/
mL (when only the father smoked). Table 1 shows
that several available chromatography methods have
detection limits ranging from 0.1 to 0.2 ng/mL while
the most sensitive immunoassay method in Table 2
reports a 0.3 ng/mL detection limit.
The question of analyte volatility losses during
analysis was discussed, and it was generally agreed
that if nicotine were included as an analyte, precau-
tions would need to be taken to prevent loss during
concentration steps. Acidification to convert nicotine
to a salt form prevents losses during concentration.
Cotinine primary standards are used in the free
base form by some analysts; however, a salt form was
preferred by meeting participants, since the free base
form is hygroscopic and difficult to maintain at a
well-defined purity. A perchlorate salt of cotinine was
recommended for preparation of 1 mg/mL stock solu-
tions in 0.01 N HCl (8). This standard solution could
be frozen and kept indefinitely. The group consensus
was that a salt form of cotinine should be made avail-
able as a primary standard.
Chemical analysis is usually accomplished by gas
chromatography with nitrogen/phosphorus thermi-
onic detection (GC-NPD) or GC-mass spectrometry
(GC-MS) using either electron impact ionization or
chemical ionization. Packed columns for GC were suc-
cessfully used; however, fused silica capillary columns
containing a methyl silicone or methyl phenyl silicone
liquid phase were recommended (see Table 1 HRGC
references).
A high-performance liquid chromatography
(HPLC) method using a C18 reversed phase column
with paired ion chromatography and UV detection (at
257 nm) was also reported by McElroy where the
HPLC method of Machacek and Jiang (14) was modi-
fied for analyzing urine samples at passive exposure
levels. Further improvement in HPLC sensitivity and
detection limit is required before application to the
more limited sample volumes generally available for
blood or saliva. HPLC was considered a very promis-
ing approach due to the highly efficient columns now
available and the stability and reproducibility of
response commonly obtainable by UV detection.
The final quantitation of residues in all methods
was accomplished with internal standards and stan-
dard curves developed from fortified blank samples.
It was recommended that standard curves be pre-
pared daily or with each batch of samples. A variety
of internal standards were used ranging from deuter-
ated cotinine and nicotine for GC-MS to chemically
similar compounds for other GC or LC detectors.
Table 1 lists the chromatography methods (14-17)
presented at the workshop and summarizes the sali-
ent features of each. Information for this table was
derived from questionnaire responses submitted by
each author/participant.
Chromatography Group
Recommendations
The chromatography group recommended that an
interlaboratory methods comparison study be con-
ducted prior to any large-scale monitoring efforts
aimed at determining population exposure to tobacco
smoke. Specific suggestions and recommendations
relating to method comparison studies were as
follows:
*Separate studies should be conducted for passive
exposure levels and active smoker levels.
* Statisticians should be used in planning study
samples.
* Blood, urine, and saliva should be included in each
study.
* Immunoassay and chromatography methods should
be included in each method comparison study.
* Samples should be fluids from exposed individuals
and also from fortified blanks in order to look for
bias from chromatography or immunoassay methods
through measurement of artifacts or metabolites
related to nicotine/cotinine.
*The study coordinator should supply standard refer-
ence material(s) to each participating laboratory.
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Table 1. Summary of passive exposure chromatography methods.
Machacek and Feyerabend et al. Kornfeld (personal
Jiang (14) Jacob, et al. (15) Verebey et al. (16) (17) communication)
Sample type Urine Blood, plasma, Serum All biological fluids Urine
urine
Vol. analyzed, mL 6 1 0.5 1 5
Concentration step N2 evaporated to N2 evaporated to None N2 evaporated to N2 evaporated
dryness dryness dryness solvent exchange
Extraction method SPE column Solvent extraction Solvent extraction Solvent extraction Solvent extraction
Chloroform elution
Isolation step Acid/base partition Acid/base partition Acid/base partition None: plasma and None
saliva
back extract
urine
Determination HPLC reverse-
phase
Paired ion HRGC-NPD HRGC-NPD GC-NPD HRGC-MS
chromatography
HRGC-MS
Quantitation Internal standard Internal standard Internal standard Internal standard Internal standard
Calibration curve Calibration curve Calibration curve Calibration curve Calibration curve
Linear range 0-500 ng 0-4000 ng/mL 40-400 ng/mL 0-15,000 ng/mL 1-500 ng/mL
Detection limit <1 ng/mL 0.2 ng/mL 5 ng/mL 0.1 ng/mL 0.13 ng/mL
Quantification limit 1 ng/mL 0.5-5 ng/mL 5 ng/mL 0.1 ng/mL 0.25 ng/mL
CV, % 13 6.8 (3.0 ng/mL) 5.6 7.7 6
12 (1.0 ng/mL)
13 (0.5 ng/mL)
% recovery 90 107 90 90 85
Immunoassay Group Report General Method Considerations
Participants in the workshop with expertise in the Introduction. The first radioimmunoassay (RIA)
development and use of immunoassays for detecting for cotinine was reported in 1973 (18,19). Antisera
cotinine in biological fluids met independently of the were raised in rabbits and goats immunized with a
chromatography group to discuss and make recom- covalent conjugate prepared by linking cotinine 4'-
mendations regarding methodology and applications carboxylic acid to immunogenic carrier proteins, such
of immunoassay in monitoring passive as well as as bovine serum albumin and keyhole limpet hemocy-
active exposure to tobacco smoke, QA/QC programs, anin. The radioactive tracer was prepared by labeling
and interlaboratory methods comparison. The follow- a tyramine derivative of cotinine 4'-carboxylic acid
ing discussion presents an overview of the available with "I; since then, [3H]cotinine has been prepared
immunoassay techniques for cotinine analysis, their enzymatically (19) from [3H]nicotine and is now
applications with advantages and disadvantages, and widely used. Another approach uses cotinine deriva-
the views and recommendations of the immunoassay tized at the 1-position in the pyridine ring for prepar-
panel members. There is notable agreement between ing the immunogen and as a precursor of an "-I-
this group and the chromatography group on most labeled tracer (20). The original assay has been used
common issues outside the technical aspects specific to measure cotinine levels in physiological fluids, e.g.,
to each methodology. urine, blood, saliva, amniotic fluid, and spinal fluid
Table 2. Summary of immunoassay methods.
Langone et al. (18)
Langone and Van
Vunakis (19) Haley et al. (22) Knight et al. (29) Bjercke et al. (27,28)
Sample type and volume Urine (0.02-0.05) Urine, plasma, saliva Urine (0.01) Urine, serum, saliva
analyzed, mL Serum (up to 0.5) (0.005-0.025) Serum (0.1) (0.1 in RIA; 0.01 in
Saliva (0.02) microtiter plate
assays)
Assay type RIA (25I, 3H) RIA (3H) RIA (125I) RIA (125I, 3H), ELISA,a
FIA
Quantitation Internal standard Internal standard Internal standard Internal standard
Calibration curve Calibration curve Calibration curve Calibration curve
Detection limit, ng/mL 2 0.37 0.3 0.5-1.5
Quantitation limit, ng/mL 2 1 1 0.5-1.5
CV, % 6-10 10 10-15 9-14
aEnzyme-labeled protein A cannot be used to assay concentrated serum.
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(18,19,21-23) of active smokers and serum, urine, and
saliva (24-26), of passive smokers.
More recently, monoclonal antibodies specific for
cotinine have been prepared and used to develop fluid
phase RIAs with the 1"I- and 3H-labeled tracers as
well as enzyme-linked immunosorbent assays
(ELISA) and a fluorescence immunoassay (FIA) in a
microtiter plate format (27,28). These assays also
have been used to measure cotinine levels in fluids of
active (27,28) and passive smokers (Langone et al.,
unpublished results).
Test Samples and Standards. Because the origi-
nal RIAs and the monoclonal antibody-based
nonisotopic assays have been developed for analysis
of unextracted physiological fluids, careful attention
must be paid to possible nonspecific inhibition of
antigen-antibody binding resulting from effects of pH
or high concentrations of salts or urea, e.g., in urine.
In this regard the immunoassay group agreed and
strongly recommended that pooled standard samples
of serum, saliva, and urine containing known amounts
of added or endogenous cotinine should be made
available through an agency such as the National
Institute of Standards and Technology. There was
general agreement that GC/MS would be the best
method to establish the cotinine concentration for
purposes of methods comparison and that levels
should cover the range from cotinine-free through
concentrations found in passive and active smokers.
Essentially cotinine-free samples might be collected
from a population that would represent a group with
minimal exposure to tobacco smoke (e.g., Mormons in
Utah). The suggestion also was made that low-level or
essentially cotinine-free fluids might be treated (e.g.,
by absorption with XAD-2 resin or charcoal) to
remove possible traces of cotinine. However, because
absorption could remove other constituents that
might affect the assays, it was not considered to be a
firm recommendation.
Although it was suggested that urine may be the
fluid of choice for RIA analysis, there was no strong
consensus for priority over serum or saliva. In this
regard, one participant pointed out the advantage
that salivary cotinine levels determined by RIA are
independent of saliva flow (Van Vunakis and Regas,
unpublished results). The monoclonal antibody assays
also have been used to detect cotinine in saliva and
urine of passively exposed children (Langone et al.,
unpublished observations), and these investigators
tended to favor the use of saliva. In addition to the
use of dental rolls as discussed by the chromatogra-
phy group, one member of the immunoassay group
suggested that subjects chew a piece of Teflon tape to
stimulate the flow of saliva that is then collected in a
glass vial. It was pointed out that Teflon will not
contaminate the sample. Regardless of which fluid is
tested, it was recommended that samples be cen-
trifuged (e.g., 2000g for 10-20 min or lOOg for 1-2
min) to sediment particulate matter before analysis.
Immunoassay group participants concurred with the
sample handling recommendations given in the Chro-
matography Group Report.
Comparison of the Assays
The original RIA and variations of it are used by
the immunoassay group participants. Therefore, the
discussion focused on this method and the monoclonal
antibody based assays, the salient features of which
are summarized in Table 2.
Reagents. The same immunogen was used to pro-
duce the rabbit, goat, or sheep antisera and the
monoclonal antibodies. However, it was emphasized
that cotinine 4'-carboxylic acid (and the "2I-labeled
derivative) is a mixture of stereoisomers giving rise
to a heterogeneous population of polyclonal antibo-
dies recognizing both natural (-)-cotinine and the
(+)-enantiomer. Also, conventional antisera contain a
population of antibodies that bind specifically to the
linkage group that joins cotinine to the immunogenic
carrier protein and to the tyramine group in the 12' I-
labeled derivative. The practical consequences are a
relatively shallow standard inhibition curve and the
failure to achieve 100% inhibition of immune binding
with (-)-cotinine. Although these problems are cir-
cumvented by using (-)-[3H] cotinine, this assay is
somewhat less sensitive, owing to the lower specific
activity and counting efficiency achieved with tri-
tium. Also, disposing of large volumes of radioactive
scintillation fluid is a major concern.
Two approaches have been used with some success
to improve the quality of the 1"I-RIA with rabbit
antisera. They involve removing antibridge group
antibodies by absorption with a nicotine-hemocyanin
conjugate (29) and preparing an "M'I-labeled cotinine
derivative with a bridging group different from that
present in the immunogen (30). In contrast,
monoclonal antibodies to cotinine were produced in a
way that avoided the problems inherent in the use of
polyclonal antisera (27,28). Although the immunogen
contained a mixture of isomers, the hybridomas were
screened using (-)-[3H]cotinine to optimize chances of
detecting antibodies that preferentially recognize the
naturally occurring isomer, but not the bridging
group in the immunogen. Furthermore, it was pointed
out that monoclonal antibodies are preferred stan-
dard reagents for immunoassay because they are con-
tinuously available and are homogeneous in terms of
binding affinity and specificity.
The specificity of any newly produced antiserum
must be fully characterized one time with a battery of
compounds that would include at least cotinine, nico-
tine, and metabolites such as nicotine N'-oxide, nor-
nicotine, and trans-3'-hydroxycotinine. This
recommendation holds even for new antisera pre-
pared with a proven immunogen, since the response of
individual immunized animals cannot be predicted.
However, all agreed that when the properties of the
antiserum had been established, it was unnecessary
for each laboratory that received that antiserum to
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complete a thorough reexamination of specificity,
although it would be good laboratory practice to rou-
tinely compare the cotinine and nicotine inhibition
curves.
Immunoassay methods have often reported using
standard cotinine as the free base. However, because
cotinine is hygroscopic and difficult to weigh accu-
rately, all participants agreed that a nonhygroscopic
salt of cotinine, such as the perchlorate or fumarate,
would be the preferred standard.
Assay Performance. In the original RIA,
antibody-bound and free-labeled cotinine were sepa-
rated by the double-antibody method in which a het-
erologous antibody directed against the species of
anticotinine was used to precipitate antigen-antibody
complexes (18). Other techniques can be used includ-
ing precipitation with ammonium sulfate or polyeth-
ylene glycol (29). Although the latter methods are
faster and less expensive, there was some concern
expressed that background radioactivity precipitated
by ammonium sulfate, when normal serum is used in
place of anti-cotinine, can exceed 10% of the added
amount of cotinine tracer.
In contrast to the conventional fluid phase RIAs,
the monoclonal antibody-based assays are carried out
in a solid-phase system in which a cotinine-polylysine
conjugate is passively adsorbed to the surface of 96-
well plastic microtiter plates (27,28). Immobilized
cotinine and fluid phase cotinine in the test sample
compete for monoclonal anticotinine, which is
detected with a variety of enzyme-labeled antiimmu-
noglobulin reagents including the bacterial product,
protein A. Assay sensitivity can be enhanced by using
a sandwich procedure in which rabbit anti-mouse
immunoglobulin is added before (or along with)
labeled protein A. It was emphasized that protein A
reagents cannot be used to detect low levels of serum
cotinine, because host IgG will bind nonspecifically to
the microtiter wells giving high background binding
of the enzyme-labeled protein A tracer.
Compared to times when rabbit antisera were used,
assays with monoclonal antibodies were more sensi-
tive, the standard curves were steeper, and the anti-
gen-antibody reaction was completely inhibited by
(-)-cotinine, even when the 125I-labeled tyramine
derivative was used in RIA (28). There was good
agreement between the levels of cotinine found in
saliva and serum of smokers determined by conven-
tional RIA, the monoclonal antibody ELISA and GC
(27,28). It was pointed out that high quality rabbit
antisera also can be used in the solid phase
nonisotopic immunoassays with titers that can be
100- to 1000-fold higher than in RIA (27,28).
Speciflcity and Sensitivity. Both polyclonal and
monoclonal antibodies are specific for cotinine
(18,19,27). Approximately 50 to 100 compounds that
have been tested in the immunoassays including sev-
eral nicotine metabolites, related tobacco alkaloids,
and other compounds that retain structural features
of either or both ring systems found in nicotine or
cotinine fail to inhibit the antigen-antibody reactions
at levels that would interfere in the assays.
One participant emphasized that literally
thousands of serum and urine samples from both
active smokers and nonsmokers had been analyzed
over a period of several years and that few, if any,
false positives had been reported. Although the sub-
jects studied are mainly from the U.S. and England,
these data support the view that diet or other factors
such as prescription or other drugs do not interfere in
the assays and are consistent with high specificity of
anticotinine. It was pointed out that differences in
diet or drug use must be considered when other popu-
lations are studied, or at least be aware that interfer-
ence in the assays might arise from factors which
have not appeared to date.
The immunoassays generally can detect cotinine
down to the ng/mL level or less (Table 2), although it
was emphasized that sensitivity can be affected by
the need to dilute samples (e.g., urine) that may give
spurious results when higher concentrations are
tested. This point was discussed at some length with
the participants in agreement that a sensitivity for
cotinine of 0.1 ng/mL of physiological fluids could not
generally be achieved with confidence using the avail-
able immunoassays. In this regard, it was pointed out
that differences in sensitivity limits between chroma-
tography and immunoassay likely reflect fundamen-
tal differences in methodology and are not strictly
comparable. GC methods, for example, might extract
and analyze a considerably larger portion of sample
than would be analyzed by immunoassay.
Analytical Results. There was general agreement
that cotinine concentration should be expressed as
nanogram per milliliter. However, urine values also
should be given as nanogram per milligram creati-
nine, as this ratio is used conventionally in the medi-
cal literature to account for differences in urine
volume. Because low levels of creatinine in infants
relative to adults may result in misleading values
that fall into the range reported for active smokers,
the need to include primary data for urine was
stressed. Furthermore, experience has shown that
urinary cotinine levels determined by conventional
RIA generally are 30 to 50% higher than values
obtained for the same samples by GC. Discussion cen-
tered on the possibility that the higher RIA values
may reflect cross-reactivity of anti-cotinine with
trans-3'-hydroxycotinine, which recently has been
reported to be a major nicotine metabolite found in
smokers' urine at levels up to three times higher than
cotinine (31).
Since this meeting, synthetic trans-3'-hydroxyco-
tinine (supplied by Dr. Peyton Jacob, San Francisco
General Medical Center) has been shown to cross-
react only 1 to 2% compared to cotinine in the
monoclonal antibody based ELISA; one participant
stated that he found only about 5% cross-reactivity
with his rabbit antiserum in RIA. This degree of
cross-reaction would not account for the discrepancy
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Table 3. Summary comparison of chromatography and RIA methods.
Chromatography methods RIA methods
Sample type Blood, saliva, urine Blood, saliva, urine
Vol. analyzed, mL 0.5-6 0.005-0.5
Extraction and concentration Yes No
Quantification Internal standard Internal standard
Calibration curve Calibration curve
Detection limit, ng/mL 0.1-5 0.3-2
Quantification limit, ng/mL 0.1-5 0.5-2
CV, % 5.6-13 6-15
in the urine values, and it was agreed that further
research was needed to clarify the basis for the
differences.
Considerations in Selecting an
Analytical Technique
Table 3 shows some comparisons for RIA and chro-
matography methods. Apparent differences are in
sample volumes used, sample work-up requirements,
and limits of detection. RIA methods use less than
10% ofthe sample volumes required for chromatogra-
phy methods, and this is a major reason that RIA
detection limits are not as low as those for chroma-
tography methods. Because RIA methods do not
require sample manipulations such as extraction and
concentration, they are faster, simpler, and presuma-
bly less expensive. Chromatography procedures not
only have the advantage of increased sensitivities, but
also are more specific and can provide quantification
of both nicotine and cotinine in a single analysis.
Workshop participants agreed that the choice
between these two approaches would depend on the
goals of a particular study. Both approaches have
been found to be 100% effective in discriminating
smokers from nonsmokers (32). This particular goal
would favor the use of an RIA method. At least one
participant suggested that the more sensitive chro-
matography methods are recommended to character-
ize ETS exposures for plasma or saliva concentrations
when levels are less than 1 ng/mL.
A compilation of literature values for cotinine con-
centrations in body fluids of nonsmokers before and
after documented ETS exposures is shown in Table 4.
This comparison indicates a similarity between
plasma and saliva concentrations, while urine values
are often a factor of two or more higher. This is a
primary reason that urine is often the fluid of choice
when RIA methods are used in passive smoking
studies.
Quality Assurance for Laboratories
Assaying Cotinine
Participants in the cotinine workshop discussed the
need for developing a quality assurance (QA) pro-
gram for monitoring performance of laboratories
assaying cotinine for the purpose of assessing expo-
sure to ETS. When assuming many subjects, such a
QA program would be essential to ensure that the
conclusions reached are based on reliable data. A one-
time exercise where the ability of laboratories to
measure cotinine levels found in both active smoking
and for passive exposure to ETS was considered as an
alternative possibility. This suggestion was prompted
by the realization that although published data on
cotinine levels found in body fluids for active smokers
show reasonable agreement, levels of cotinine
reported for subjects exposed to ETS show considera-
ble variation. Such differences might not be unex-
pected when measuring the low levels of cotinine
found in ETS exposure, given that the detection limits
for existing analytical methods approximate these
cotinine levels.
To evaluate the between-laboratory variation in
cotinine analyses, an international study was initi-
ated by the Forschungsellschaft Rauchen and
Gesundheit mBH in Hamburg (32). Eleven laborato-
ries experienced in measuring nicotine and cotinine
by RIA and/or GC participated. Serum and urine
specimens from eight nonsmokers and eight smokers,
and from two nonexposed nonsmokers spiked with
nicotine and cotinine were distributed on dry ice to
each laboratory. Results were returned and analyzed
by method and by laboratory. Recoveries on both the
urine and serum specimens spiked with cotinine cor-
responding to levels found in smokers ranged from 79
to 119%, with the exception of one laboratory with a
20% recovery (the data from this laboratory were
excluded from further analysis). The interlaboratory
coefficient of variation on these same samples was
excellent (9-13%). The coefficient of variation on
samples from smokers was fairly large, however,
ranging from 18 to 45% for serum and 21 to 59% for
urine. Further, cotinine levels reported for urine were
about 60% higher than from those using RIA as com-
pared to GC, suggesting a possible interfering sub-
stance in the immunoassay system. Cotinine levels
reported for nonsmokers were extremely variable,
and a number oflaboratories could not detect cotinine
in serum from exposed nonsmokers. In addition,
cotinine values reported by some laboratories bore no
relationship to estimated ETS exposure, or they were
so high as to be unrealistic. In spite ofthis variability,
all laboratories were able to discriminate smokers
from nonsmokers with 100% effectiveness.
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Table 4. Mean or median concentrations of cotinine in nonsmokers before and after exposure to environmental tobacco
smoke.
Plasma cotinine, Saliva cotinine, Urine cotinine,
Study reference ng/mL ng/mL ng/mL
Before After Before After Before After
(33) 0.82 2.04 0.73 2.48 1.55 7.71
(34) 1.1 7.3 1.5 8.0 4.8 12.9
(9) 0.8 1.8-2.5 0.7 2.2-2.8 1.5 6.5-9.4
(13) 0.4 1.3-3.4
(35) 0.9-1.7 2.6-3.3 1.0-1.7 1.4-2.5 14 21-55
(36) 8.5 25.2
(25) 2.8-29.6
(37) 1.3-1.7 2.4-5.6
The cotinine results reported for ETS exposure
should be viewed with caution, however. A number of
the participants at this conference workshop, who
also were in the study, indicated that the volumes
provided were insufficient for repeat analysis using
GC or an assay was used which had not been opti-
mized for measuring passive levels of cotinine. A fur-
ther limitation of the study was that recovery of
spiked cotinine was only assessed for smoking levels.
Finally, immunoassays based on monoclonal antibo-
dies were not included, nor were HPLC methods
evaluated.
This interlaboratory study indicates the need for
further information on the reliability of data pro-
vided by laboratories for study subjects exposed to
ETS. A quality assurance program could provide such
information, as well as an ongoing assessment of
quality and a mechanism for improving performance.
QA Recommendations
Interlaboratory QA. The need for an
interlaboratory quality assurance program was
endorsed by most of the session participants, with
some concern being expressed that the number of
samples evaluated be kept to reasonable limits to
minimize unnecessary assays. It was recommended
that such a program should be administered by a QA
coordinator laboratory. The coordinating laboratory
would be responsible for monitoring the performance
of participating laboratories and for providing speci-
fied samples as standards and/or controls. This labo-
ratory should have in-house expertise or have access
to laboratories having expertise in both immunoassay
and high resolution gas chromatography/mass spec-
trometry (HRGC-MS).
Suggested objectives of the QA coordinator labora-
tory include:
*To provide an objective measure of the precision and
accuracy of analytical methods used routinely by
laboratories assaying cotinine.
* To identify preferred method(s) for measuring
cotinine.
*To assess the reliability of results provided by dif-
ferent laboratories.
*To provide a mechanism for improving performance
through knowledge of the performance of others.
*To serve as a resource center for communication and
exchange of information among participants.
Recommended mechanisms for accomplishing the
foregoing objectives are as follows:
Interlaboratory Quality Assurance Studies:
Quality Assurance Samples. The coordinator labo-
ratory should periodically conduct a blind or check
sample study consisting of authentic biological fluids
(serum, urine, or saliva) with actual or spiked levels
of cotinine. Samples should be selected to represent
cotinine levels typical of those found in passive and
active smoking. Authentic biological samples with
actual levels of cotinine are strongly recommended
because only they will contain nicotine metabolites or
other substances that may interfere in assays. In
addition, blank samples spiked with known levels of
cotinine should be distributed to evaluate recovery.
Finally, samples with high levels of cotinine should be
diluted with negative specimens to check for linearity.
Samples should ideally have target values assigned by
the QA coordinating laboratory through use of refer-
ence methods. Data returned by participants would be
analyzed and reports containing results and a critique
distributed.
Field Study Samples. The QC coordinating labo-
ratory may assist organizations carrying out field
studies in assessing the performance of the study lab-
oratory on actual study subjects. The workshop con-
sidered that this could be accomplished by submission
at intervals of blind duplicates: duplicates of the same
study subject submitted at intervals to assess preci-
sion; split samples: sample is split with one portion
being sent for analysis to the study laboratory and
one portion to the QC coordinating laboratory for
comparison purposes; blanks: samples that are con-
sidered free of analyte to serve as a check on environ-
mental contamination.
Ancillary Activities of the QA Coordinating
Laboratory: Primary Reference Standard(s). A
strong consensus was reached that a well-character-
ized, pure, primary reference standard be made avail-
able. This material should be aliquoted into
quantities sufficient to allow any laboratory to use
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the standard for assay calibration. Handling and
storage information should also be provided along
with suggested methods for preparing secondary
standards. It was generally agreed that cotinine
should be in the form of a salt, since cotinine freebase
is hygroscopic and, therefore, likely to vary in compo-
sition dependent on handling conditions. The perchlo-
rate salt was suggested as one possibility (see
chromatography group report). It was further recom-
mended that the standard be supplied in solution to
preclude errors due to dilution. The GC group made
the suggestion that the National Institute of Stan-
dards and Technology might be the appropriate
agency to prepare such a standard. The QC coordinat-
ing laboratory could then distribute the standard.
Biological Reference Samples. The suggestion
was made that, in addition to providing a primary
reference standard, the QA coordinating laboratory
make available authentic biological samples from
actual smokers and subjects exposed to ETS. Cotinine
concentrations would be established by the QA coor-
dinating laboratory using a reference method(s) and
declared on each reference sample. Such samples
would be important because the cotinine would be
present in the matrix (urine, serum, saliva) actually
used by analysts, thus allowing evaluation of possible
matrix interference. In addition, such specimens
would contain nicotine, nicotine metabolites other
than cotinine, and other substances which might
interfere in the assay.
The GC group also felt that blank samples, i.e.,
those essentially free of cotinine would be desirable.
Suggested sources were bovine serum or human sam-
ples with very low exposure to ETS. Pooled specimens
might be necessary because obtaining sufficient vol-
ume of biological reference samples could prove diffi-
cult. Samples would therefore be provided in
restricted quantities only to allow laboratories to
periodically evaluate their own method.
Reference Method. Workshop participants also
discussed a reference method for establishing
cotinine levels in biological samples. The consensus of
the group was that GC/MS would be the ultimate
reference method because of its extreme specificity.
However, in the group discussion, the GC group
pointed out that although the method is highly spe-
cific, it ultimately is no better than the reliability of
the extraction and evaporation methods chosen to
prepare samples for analysis. A further concern was
that differences in assigned values may result from
differences attributable to the detection method
(chemical ionization or electron impact). Conse-
quently, it appears unlikely that a gold standard will
be available and acceptance of a reference method
will depend ultimately on judgment of its reliability.
Representatives of the National Institute of Stan-
dards and Technology indicated that their practice is
to evaluate a variety of independent methods, and if
sufficient agreement is reached, a certified value is
provided, albeit with the understanding that confi-
dence limits are somewhat uncertain. In the absence
of agreement between various methods, NIST pro-
vides a consensus value(s) for informational purposes.
In the event that GC/MS is adopted as a reference
method, the implication for immunoassayists is that
their performance would be judged against this stan-
dard. Judging immunoassay results against GC/MS is
not without precedent, since other immunoassays,
such as those for steroids, are already compared to
this method.
Postscript
A cotinine spiked, freeze-dried human urine refer-
ence material is being prepared by the National Insti-
tute of Standards and Technology (formerly the
National Bureau of Standards). Three lots with dif-
ferent cotinine concentration levels are being pre-
pared: a) an unspiked blank level (< 1 ppb), b) an
approximately 50 ppb low level, and c) an approxi-
mately 500 ppb high level. This material (EPA/NIST
Reference Material 8444) is planned for issue during
the first quarter of 1989. The material may be ordered
from: Office of Standard Reference Materials, Build-
ing 222 Room B-311, National Institute of Standards
and Technology, Gaithersburg, MD 20899. Telephone
301-975-6776. Technical information may be obtained
from Dr. Lane Sander, Organic Analytical Research
Division, Center for Analytical Chemistry, NIST,
Gaithersburg, MD 20899. Telephone 301-975-3117.
A cotinine perchlorate salt reference material is
also being planned for development by NIST. A date
has not been determined, however, for release of this
standard.
The research described in this report has been reviewed by the
Health Effects Research Laboratory, U.S. Environmental Protec-
tion Agency, and approved for publication. Approval does not sig-
nify that the contents necessarily reflect the views and policies of
the Agency nor does mention of trade names or commercial prod-
ucts constitute endorsement or recommendation for use.
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